Doxorubicin-vincristine therapy for Wilms' tumor: a pilot study.
Doxorubicin plus vincristine chemotherapy was given to 31 children following nephrectomy for Wilms' tumor. Radiation therapy was used as indicated. Disease-free survival by stage is: eight of nine patients (stage I), eight of nine (stage II), nine of ten (stage III), and two of three (stage IV). Median follow-up of survivors is 28 months (range, 2-67); for all but four patients, follow-up is greater than 12 months. Two of the three stage I-III failures occurred in children with unfavorable histologies; the third failure was due to fatal anthracycline cardiomyopathy. Lowering the maximal cumulative doxorubicin dose from 450 to 240 mg/m2 did not increase failures. Doxorubicin-vincristine appears to be effective chemotherapy for Wilms' tumor.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009392:Nephrectomy; D014750:Vincristine / Q000627:therapeutic use*; D009396:Wilms Tumor / Q000188:drug therapy* / Q000532:radiotherapy
D014750:Vincristine; D004317:Doxorubicin